Theseus Pharmaceuticals, Inc. (THRX)
Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Inactive · Last trade price on Feb 13, 2024

Theseus Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec '22 Dec '21 Dec '20 Dec '19
Cash & Equivalents
46.8994.61244.668.461.32
Short-Term Investments
158.23103.37000
Cash & Cash Equivalents
205.12197.98244.668.461.32
Cash Growth
-3.44%-19.08%2793.01%542.14%-
Other Current Assets
4.464.143.310.110.06
Total Current Assets
209.59202.12247.978.571.38
Property, Plant & Equipment
4.334.750.0100
Long-Term Investments
20.3113.82000
Other Long-Term Assets
0.41.762.950.040.04
Total Long-Term Assets
25.0420.332.960.040.05
Total Assets
234.63222.45250.938.611.43
Accounts Payable
1.314.9711.130.29
Current Debt
0.760.74000
Other Current Liabilities
4.935.412.680.460.33
Total Current Liabilities
711.133.681.60.62
Long-Term Debt
2.93.24000
Other Long-Term Liabilities
0.210.470.8203.36
Total Long-Term Liabilities
3.13.70.8203.36
Total Liabilities
10.1114.834.51.63.98
Total Debt
3.663.98000
Common Stock
379.95320.19308.0100.81
Retained Earnings
-155.08-112.19-61.58-34.27-10.22
Comprehensive Income
-0.35-0.39000
Shareholders' Equity
224.52207.62246.43-34.27-9.41
Net Cash / Debt
201.47194244.668.461.32
Net Cash / Debt Growth
-3.29%-20.71%2793.01%542.14%-
Net Cash Per Share
4.605.0425.4014.888.28
Working Capital
202.58190.99244.296.980.77
Book Value Per Share
5.135.3925.59-60.28-59.17
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).